TY - JOUR T1 - Successful S-1 Monotherapy for Chemorefractory Thymic Carcinoma JF - Anticancer Research JO - Anticancer Res SP - 299 LP - 301 VL - 31 IS - 1 AU - TOMONOBU KOIZUMI AU - TOSHIHIKO AGATSUMA AU - YOSHIMICHI KOMATSU AU - KEISHI KUBO Y1 - 2011/01/01 UR - http://ar.iiarjournals.org/content/31/1/299.abstract N2 - The optimal chemotherapeutic regimen for inoperable thymic carcinoma remains uncertain and little information is available regarding the usefulness of salvage chemotherapy. S-1, a newly developed oral fluorouracil antitumor drug, has been reported to be effective in the treatment of gastrointestinal tumors and non-small cell lung cancer. This case study reports a case of chemorefractory thymic cancer with a good response to S-1 monotherapy. S-1 was used as sixth-line chemotherapy and the response was the first remarkable tumor regression in the patient's clinical course. S-1 appears to have significant activity against thymic carcinoma. ER -